Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

(2015) Ji Hyun Park et al.   BMC CANCER

Basal expression of insulin-like growth factor 1 receptor determines intrinsic resistance of cancer cells to a phosphatidylinositol 3-kinase inhibitor ZSTK474

(2015) Sho Isoyama et al.   CANCER SCIENCE

Phase II study of PX-866 in recurrent glioblastoma

(2015) M. W. Pitz et al.   NEURO-ONCOLOGY

The PI3K-PKB/Akt Pathway

(2015) Brian A. Hemmings et al.   Cold Spring Harbor Perspectives in Biology

A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer

(2014) A. Jimeno et al.   ANNALS OF ONCOLOGY

PP242 suppresses cell proliferation, metastasis, and angiogenesis of gastric cancer through inhibition of the PI3K/AKT/mTOR pathway

(2014) Xiaofang Xing et al.   ANTI-CANCER DRUGS

DEAD-box helicase DP103 defines metastatic potential of human breast cancers

(2014) Eun Myoung Shin et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

(2014) L Molife et al.   Journal of Hematology & Oncology

Prognostic implication of TSC1 and mTOR expression in gastric carcinoma

(2014) Sun-ju Byeon et al.   JOURNAL OF SURGICAL ONCOLOGY

Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus

(2014) Pengda Liu et al.   NATURE

Making new contacts: the mTOR network in metabolism and signalling crosstalk

(2014) Mitsugu Shimobayashi et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors

(2014) Filip Janku et al.   Cell Reports

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

(2013) Pascal Furet et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

(2013) Howard A. Burris   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110  Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

(2013) J. T. Garrett et al.   CANCER RESEARCH

AEG-1 Is a Target of Perifosine and Is Over-Expressed in Gastric Dysplasia and Cancers

(2013) Wenbin Huang et al.   DIGESTIVE DISEASES AND SCIENCES

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer

(2013) CHANG-HUA ZHANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere

(2013) Jing Li et al.   Journal of Translational Medicine

BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models

(2013) Ningshu Liu et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer

(2013) Z. A. Wainberg et al.   MOLECULAR CANCER THERAPEUTICS

Genetic variations of mTORC1 genes and risk of gastric cancer in an eastern chinese population

(2013) Jing He et al.   MOLECULAR CARCINOGENESIS

Amino acid signalling upstream of mTOR

(2013) Jenna L. Jewell et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth

(2013) SONG LIANG et al.   ONCOLOGY REPORTS

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-Fluorouracil inPIK3CAmutant gastric cancer cells

(2012) Bhaskar Bhattacharya et al.   CANCER BIOLOGY & THERAPY

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

(2012) Annett Mueller et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) D. S. Hong et al.   CLINICAL CANCER RESEARCH

VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer

(2012) S. Hart et al.   MOLECULAR CANCER THERAPEUTICS

Characterization of the Mechanism of Action of the Pan Class I PI3K Inhibitor NVP-BKM120 across a Broad Range of Concentrations

(2012) S. M. Brachmann et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

(2012) B. R. Davies et al.   MOLECULAR CANCER THERAPEUTICS

MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells

(2012) DONGXIAO LIU et al.   Molecular Medicine Reports

Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: A novel mechanism of PTEN inactivation

(2012) Zhen Yang et al.   Clinics and Research in Hepatology and Gastroenterology

MicroRNA-21 Modulates Chemosensitivity of Breast Cancer Cells to Doxorubicin by Targeting PTEN

(2011) Zhao-Xia Wang et al.   ARCHIVES OF MEDICAL RESEARCH

Oncogenic AKTivation of translation as a therapeutic target

(2011) A C Hsieh et al.   BRITISH JOURNAL OF CANCER

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [ 18 F]FLT Uptake

(2011) Thorsten Fuereder et al.   CLINICAL CANCER RESEARCH

Antitumor Activity of NVP-BKM120--A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

(2011) D. Koul et al.   CLINICAL CANCER RESEARCH

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

(2011) EUNJU PARK et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

(2011) Johanna C. Bendell et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

(2011) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Structural Basis for Activation and Inhibition of Class I Phosphoinositide 3-Kinases

(2011) Oscar Vadas et al.   Science Signaling

Forkhead transcription factors: key players in health and disease

(2011) Bérénice A. Benayoun et al.   TRENDS IN GENETICS

ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system

(2010) De-xin Kong et al.   ACTA PHARMACOLOGICA SINICA

Blocking of PI3K/AKT induces apoptosis by its effect on NF-κB activity in gastric carcinoma cell line SGC7901

(2010) Xu Chao et al.   BIOMEDICINE & PHARMACOTHERAPY

MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN

(2010) Zhang Chun-zhi et al.   BMC CANCER

Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT

(2010) Christopher R. Garrett et al.   INVESTIGATIONAL NEW DRUGS

Ras Homolog Enriched in Brain (Rheb) Enhances Apoptotic Signaling

(2010) Sascha Karassek et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine

(2010) Antonella Perotti et al.   JOURNAL OF CLINICAL ONCOLOGY

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

(2010) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

RIP1 Activates PI3K-Akt via a Dual Mechanism Involving NF- B-Mediated Inhibition of the mTOR-S6K-IRS1 Negative Feedback Loop and Down-regulation of PTEN

(2009) S. Park et al.   CANCER RESEARCH

Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer

(2009) G. Yu et al.   CLINICAL CANCER RESEARCH

Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt

(2009) Dong Bai et al.   INTERNATIONAL JOURNAL OF CANCER

The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray

(2009) Li Xiao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling

(2008) Tsuneo Ikenoue et al.   EMBO JOURNAL

The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C

(2008) Valeria Facchinetti et al.   EMBO JOURNAL

Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis

(2008) S. Maddika et al.   JOURNAL OF CELL SCIENCE

Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues

(2008) Junming Guo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint

(2008) Dana M. Gwinn et al.   MOLECULAR CELL

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

FOXOs, cancer and regulation of apoptosis

(2008) Z Fu et al.   ONCOGENE

Activated Akt as an indicator of prognosis in gastric cancer

(2008) Caterina Cinti et al.   VIRCHOWS ARCHIV